274 related articles for article (PubMed ID: 28699369)
1. Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003-2012 in a Danish population.
Christiansen FE; Pedersen TB; Juel J; Kirkeby HJ
Scand J Urol; 2017 Oct; 51(5):392-396. PubMed ID: 28699369
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
[TBL] [Abstract][Full Text] [Related]
3. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
Kennelly M; Dmochowski R; Schulte-Baukloh H; Ethans K; Del Popolo G; Moore C; Jenkins B; Guard S; Zheng Y; Karsenty G;
Neurourol Urodyn; 2017 Feb; 36(2):368-375. PubMed ID: 26607743
[TBL] [Abstract][Full Text] [Related]
5. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity.
Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Marque P; Rischmann P; Gamé X
World J Urol; 2016 May; 34(5):755-61. PubMed ID: 26282099
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
Marcelissen TA; Rahnama'i MS; Snijkers A; Schurch B; De Vries P
World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
[TBL] [Abstract][Full Text] [Related]
12. Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.
Avallone MA; Sack BS; El-Arabi A; Guralnick ML; O'Connor RC
Neurourol Urodyn; 2017 Apr; 36(4):1104-1107. PubMed ID: 27283922
[TBL] [Abstract][Full Text] [Related]
13. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
Peyronnet B; Castel-Lacanal E; Manunta A; Roumiguié M; Marque P; Rischmann P; Gamé X
Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
[TBL] [Abstract][Full Text] [Related]
14. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
15. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S
World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
[TBL] [Abstract][Full Text] [Related]
17. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
Ferreira RS; D'Ancona CAL; Oelke M; Carneiro MR
Einstein (Sao Paulo); 2018 Aug; 16(3):eAO4207. PubMed ID: 30088545
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
[TBL] [Abstract][Full Text] [Related]
19. Intravesical Electromotive Botulinum Toxin Type "A" Administration for Management of Urinary Incontinence Secondary to Neuropathic Detrusor Overactivity in Children: Long-term Follow-up.
Ladi-Seyedian SS; Sharifi-Rad L; Kajbafzadeh AM
Urology; 2018 Apr; 114():167-174. PubMed ID: 29229221
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes.
Habashy D; Losco G; Tse V; Collins R; Chan L
BJU Int; 2015 Oct; 116 Suppl 3():61-5. PubMed ID: 26176660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
